Cure enters this GSL Season 2 Group Stage 1 BO3 matchup as the clear favorite against sOs, reflecting his stronger recent form and higher consistency in TvP. The Korean Terran has posted solid results through the 2026 season, advancing deep in prior GSL events and demonstrating reliable macro play alongside strong map control. Veteran Protoss sOs, known for creative builds and late-game adaptability, has shown flashes but carries a mixed record in recent Code S appearances, including straight-set losses in group play. The group features additional strong Terrans like ByuN and SHIN, raising the stakes for early wins, while map pool factors such as Ruby Rock LE could influence early aggression or macro transitions. Trader consensus aligns with Cure's edge based on head-to-head trends and current ladder standings.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоCure – sOs




Moneyline
$110 Обс.
Map 1 Winner
$860 Обс.
Map Handicap
$100 Обс.
Total Games
$100 Обс.
This market will resolve to "Cure" if Cure win the match against sOs.
This market will resolve to "sOs" if sOs win the match against Cure.
If the match is canceled (not played at all), ends in a tie, or is delayed beyond 7 days from the scheduled date without a winner determined, this market will resolve to 50-50.
If the match begins but is not completed, and one team wins due to the opponent's forfeiture, disqualification, or walkover, this market will resolve to the team who wins.
If the match ends in a forfeit, disqualification, or walkover (team withdraws before the start and the other wins automatically), this market will resolve to 50-50.
The resolution source for this market will be official information from https://liquipedia.net/starcraft2/Main_Page. However, if https://liquipedia.net/starcraft2/Main_Page has not published final results within 2 hours after the event’s conclusion, a consensus of credible reporting may be used instead including video evidence.
In cases where a team’s listed name includes minor discrepancies from the resolution source, this market will resolve based on the underlying real-world match rather than exact name matching. Recognizable abbreviations, alternate or erroneous spellings, sponsor tags, affiliate or academy designations, regional identifiers, and minor formatting differences will be treated as referring to the same team, provided the intended team can be clearly and uniquely identified within the relevant competition. If a listed team name has no reasonable connection to any participating team, or if it matches or could reasonably refer to another team in the same competition such that the intended team cannot be unambiguously determined, this market will resolve 50-50.
Ринок відкрито: May 19, 2026, 6:00 PM ET
Джерело вирішення
https://liquipedia.net/starcraft2/Main_PageResolver
0x65070BE91...Cure – sOs




Moneyline
$110 Обс.
Map 1 Winner
$860 Обс.
Map Handicap
$100 Обс.
Total Games
$100 Обс.
This market will resolve to "Cure" if Cure win the match against sOs.
This market will resolve to "sOs" if sOs win the match against Cure.
If the match is canceled (not played at all), ends in a tie, or is delayed beyond 7 days from the scheduled date without a winner determined, this market will resolve to 50-50.
If the match begins but is not completed, and one team wins due to the opponent's forfeiture, disqualification, or walkover, this market will resolve to the team who wins.
If the match ends in a forfeit, disqualification, or walkover (team withdraws before the start and the other wins automatically), this market will resolve to 50-50.
The resolution source for this market will be official information from https://liquipedia.net/starcraft2/Main_Page. However, if https://liquipedia.net/starcraft2/Main_Page has not published final results within 2 hours after the event’s conclusion, a consensus of credible reporting may be used instead including video evidence.
In cases where a team’s listed name includes minor discrepancies from the resolution source, this market will resolve based on the underlying real-world match rather than exact name matching. Recognizable abbreviations, alternate or erroneous spellings, sponsor tags, affiliate or academy designations, regional identifiers, and minor formatting differences will be treated as referring to the same team, provided the intended team can be clearly and uniquely identified within the relevant competition. If a listed team name has no reasonable connection to any participating team, or if it matches or could reasonably refer to another team in the same competition such that the intended team cannot be unambiguously determined, this market will resolve 50-50.
Ринок відкрито: May 19, 2026, 6:00 PM ET
Джерело вирішення
https://liquipedia.net/starcraft2/Main_PageResolver
0x65070BE91...Cure enters this GSL Season 2 Group Stage 1 BO3 matchup as the clear favorite against sOs, reflecting his stronger recent form and higher consistency in TvP. The Korean Terran has posted solid results through the 2026 season, advancing deep in prior GSL events and demonstrating reliable macro play alongside strong map control. Veteran Protoss sOs, known for creative builds and late-game adaptability, has shown flashes but carries a mixed record in recent Code S appearances, including straight-set losses in group play. The group features additional strong Terrans like ByuN and SHIN, raising the stakes for early wins, while map pool factors such as Ruby Rock LE could influence early aggression or macro transitions. Trader consensus aligns with Cure's edge based on head-to-head trends and current ladder standings.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоОбережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання